• PDF / 169,592 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 80 Downloads / 143 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 8 case reports In a multi–centre retrospective descriptive study involving 92 patients with palmoplantar pustulosis (PPP) or acrodermatitis continua of hallopeau (ACH) conducted between January 2014 and December 2016, 8 patients [ages and sexes not stated] were described, who developed angioedema, paradoxical psoriasis, pneumonia, hypersensitivity reaction, weight gain, HenochSchoenlein-purpura, headache and nausea or influenza-like-illness during treatment with etanercept, ustekinumab or infliximab for PPP or ACH [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. The patients who had PPP or ACH, received treatment with etanercept, ustekinumab or infliximab. Out of the 8 patients, 1 patient received treatment with etanercept and developed angioedema; 2 patients received treatment with ustekinumab and developed paradoxical psoriasis (1 patient) and pneumonia (1 patient), both these patients, discontinued treatment with ustekinumab. Five patients received treatment with infliximab and subsequently developed hypersensitivity reaction (1 patient), weight gain (1 patient), Henoch-Schoenlein-purpura (1 patient), headache and nausea (1 patient), and influenza-like-illness (1 patient); all these 5 patients discontinued treatment with infliximab. Husson B, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. Journal of the European 803520544 Academy of Dermatology and Venereology 34: 2330-2338, No. 10, Oct 2020. Available from: URL: http://doi.org/10.1111/jdv.16265

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Dec 2020 No. 1834